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means of the two devices were almost similar in each 
direction except the vertical, lateral, and pitch directions (t-
test, p < 0.0001), whereas the maximal deviations in the 
three directions were slight. The SDs were not statistically 
different in each direction except the lengthwise and roll 
directions (F-test, p < 0.05), although the SDs were small in 
the corresponding two directions for CID. 
 
Conclusion: This study suggested that 3DID could show 
positional accuracy almost similar to that of CID. However, 
further investigation is needed for use in clinical practice. 
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Purpose or Objective: CTCAE version 3 is an observation 
based grading system for oral mucositis whereas version 4 is 
based on function and intervention. Although version 4 has 
been widely adopted in clinical trials there is limited data on 
its correlation with version 3 from which considerable 
radiobiological data has been derived. The purpose of this 
study was to assess the frequency of discrepancy between 
these two grading systems. 
 
Material and Methods: Oral mucosal reactions of patients 
undergoing chemoradiation or radiation alone for oral or 
oropharyngeal cancer were graded by three radiation 
oncologists in weekly on treatment and post treatment 
clinics. CTCAE version 3 and 4 mucositis grading and patient 
factors were recorded prospectively. Differences in the rate 
of discrepancy were compared by time since the 
commencement of radiotherapy, synchronous agent and 
patient age. 
 
Results: 485 measurements were recorded for 64 patients. 
Grading from version 3 and version 4 were equal in 270 (56 %) 
measurements. In the 215 (44%) measurements where version 
3 and version 4 were not equal, discrepancies were seen in: 
Week 0-4 = 79/179 (44%); Week 5-8 = 60/163 (37%); > week 8 
= 76/143 (53%) (p=0.02); patients receiving platinum agents = 
113/316 (36%) or cetuximab= 48/70 (69%) (p<0.01); patients 
> 70 years = 26/57 (46%) or < 50 years = 21/68 (31%) (p=0.09). 
 
Conclusion: Statistically significant discrepancies were seen 
when patients receiving platinum agents were compared with 
those receiving cetuximab and in those measurements 
performed following treatment completion. These initial 
results suggest that functional/interventional based grading 
systems should be used with care in dose escalation studies 
where the healing of acute mucositis may be related to 
subsequent late damage. 
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Purpose or Objective: Acute esophagitis (AE) is a common 
side-effect of radiotherapy (RT) for lung cancer. Previous 
predictive modelling studies focussed on clinical criteria 
(such as CTC) for significant AE (such as G2 or higher). Our 
clinic uses an integrative patient care approach where Nurse-
RTTs routinely monitor symptoms and provide nursing 
interventions to manage side-effects. Therefore, Nurse-RTTs 
include with clinical scoring a note of actual symptoms 
mentioned by the patient during consultations, such as 
swallowing pain (SP). A retrospective audit of 131 patients 
was used to examine correlative patterns for SP, and hence 
to develop predictive models for SP before the start of RT. 
We propose that a predictive model will facilitate nurse/RTT-
led efforts to reduce the impact of SP on patient comfort, 
overall QoL and clinical workflow. 
 
Material and Methods: An electronic journal audit was 
performed for patients commencing curative RT for lung 
cancer between January 2013 and March 2015. All NSCLC and 
SCLC patients were included, as well as various 
dose/fractionation, chemotherapy and medication schedules. 
Exported treatment plan DVHs were merged with nursing 
data. The highest score following weekly assessments of AE 
during radiotherapy was recorded, as was the appearance of 
SP and the time point at which it was mentioned. Predictive 
models of SP were developed using multivariable regression 
and machine learning algorithms. 
 
Results: The most typical patient was treated for NSCLC at 
60-66Gy normo-fractionated with concurrent chemotherapy. 
Acute esophagitis (CTC grade 1 or higher) was observed in 
110/131 (84%) and patient-reported SP in 99/131 (76%). Pain 
medication prior to RT was marginally protective against SP 
but was not statistically significant in single-parameter 
analysis (OR 0.58, 95%CI 0.24–1.41, p=0.21). A strongly 
significant dose-volume response exists between SP and 
radiobiologically-adjusted dose to the hottest 1cc of the 
esophagus. Predictive models of SP with repeated cross-
validation accuracy of 78-84% were developed (sensitivity 88-
89%, specificity 48-75%). Trained machine learning models 
correctly predicted SP 76-84% of the time in an unseen 
validation cohort of 25 patients (sensitivity 94-100%, 
specificity 25-62%).  
 
Conclusion: An integrative nursing care approach in the RT 
clinical workflow has been used to monitor symptoms and 
intervene for treatment-related pain. The risk of one 
particular patient-centred symptom, SP, can be sensitively 
predicted with nursing and treatment planning variables. A 
future nurse-led interventional study is planned, using 
predictive modelling for swallow pain, to examine the 
possible effects of pre-treatment pain-medication or 
corticosteroids on reducing dependence on additional pain 
medication.  
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Purpose or Objective: The aim of this study was to 
investigate systemic set-up errors in head and neck (H&N) 
cancer treated with intensity modulated radiation therapy 
(IMRT) by kilovoltage (kV) cone-beam computed tomography 
(CBCT) evaluation. 
 
Material and Methods: Between September 2014 and August 
2015, 360 CBCT in 60 patients (pts) affected by histological 
confirmed H&N cancer treated with IMRT technique were 
analyzed. The majority of patients treated 45 (75 %) were 
male and only 15 (25%) were female; median age was 68 
years (range 44-88 years). The type of head and neck cancer 
treated were, oropharynx , hypopharynx, nasopharynx, larynx 
, tonsil, oral cavity and parotid cancer. All patients 
underwent planning Computerized Tomography (CT) 
simulation on supine position on a GE LightSpeed RT 16 CT 
Simulator for 2.5 mm slice thicknesses. As immobilization 
system we utilized a head-shoulder thermoplastic mask (Easy 
Frame (Candor TM)). The CT data sets were transferred to 
the Focal and Varian Eclipse treatment planning system 
through DICOM network. The target delineation was 
contoured by one Radiation Oncologist and according to 
(ICRU62) the PTVs volumes were generated by adding a 3-mm 
margin in all directions to the respective CTVs. The 
prescribed dose was 66 Gy in 30 fractions delivered to GTVs, 
54-63 Gy in 30 fractions to CTVs. The IMRT plans were 
created on the Varian Eclipse treatment planning system 
